Pomerantz Law Firm Probes Allegations Against Valneva SE Investors' Claims

Investigation Overview

Pomerantz LLP, a well-respected firm in the realm of corporate and securities class action litigation, has initiated an investigation concerning Valneva SE (NASDAQ: VALN) on behalf of its investors. This inquiry primarily revolves around allegations of possible securities fraud or other unethical practices carried out by Valneva along with certain members of its senior management. Investors who are associated with Valneva are advised to reach out to Danielle Peyton for more information regarding the ongoing investigation.

The Context of the Investigation

On March 23, 2026, Valneva, in conjunction with its development partner, Pfizer Inc., published a press release highlighting the topline results from its Phase 3 clinical trial titled "Vaccine Against Lyme for Outdoor Recreationists" (NCT05477524). Despite the companies characterizing the outcomes as favorable, they acknowledged that the vaccine had not met its primary endpoint, which has raised concerns among investors. Specifically, the report pointed out a low incidence of Lyme disease cases, which significantly impacted the stock's performance.

Following this announcement, Valneva's American Depositary Receipt (ADR) experienced a significant drop, falling by $3.83 per ADR, which translates to a decrease of approximately 37.11%, closing at $6.49 per ADR.

Who is Pomerantz LLP?

Pomerantz LLP has built a reputation over the past 85 years as a pioneer in the field of securities class actions. Founded by Abraham L. Pomerantz, often referred to as the dean of the class action bar, the firm has dedicated itself to advocating for the rights of victims of securities fraud and corporate misconduct. With offices in key cities such as New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, Pomerantz is highly regarded for its successful recovery of significant damages in favor of class members.

Join the Class Action

Investors who feel they may have been affected by Valneva’s recent performance and the aforementioned press release are encouraged to join the class action. For further details or inquiries, they can contact Danielle Peyton directly at Pomerantz LLP either by email or phone (646-581-9980, ext. 7980).

Conclusion

The ongoing investigation by Pomerantz LLP signifies a critical step for invested stakeholders in Valneva SE. The legal scrutiny underscores the importance of transparency and accountability in the corporate space, especially for firms that play a vital role in public health, such as vaccine developers. Investors should stay informed and consider their options in light of these developments.